hyou645.indd

Size: px
Start display at page:

Download "hyou645.indd"

Transcription

1

2 no.645 vol.63 no ACP ACP f CODE CN1645

3

4 TRUTH SEEKING

5 ATM INDEX NATURE REVIEWS DRUG DISCOVERY, VOLUME12, DECEMBER (2013) 2014 Access to Medicine Index. Access to Medicine Foundation

6 3 CLINICIAN Ê16 NO. 645

7 CLINICIAN Ê16 NO

8 5 CLINICIAN Ê16 NO. 645

9 CLINICIAN Ê16 NO

10 7 CLINICIAN Ê16 NO. 645

11 CLINICIAN Ê16 NO

12 9 CLINICIAN Ê16 NO. 645

13 CLINICIAN Ê16 NO inph inph inph inph possible inph possible inph probable inph possible inph probable inph definite inph

14 11 CLINICIAN Ê16 NO. 645 inph Hirono N, et al:distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci, 11, DESH inph

15 (2015) 2):an open-label randomised trial. Lancet Neurol, 14, idiopathic normal pressure hydrocephalus (SINPHONI- Kazui H, et al:lumboperitoneal shunt surgery for (2013) hydrocephalus after shunt surgery. J Neurol Sci, 328, symptoms in patients with idiopathic normal pressure Kazui H, et al : Predictors of the disappearance of triad Brain and Nerve Neurologia medico-chirurgica, 52, (2012) normal pressure hydrocephalus :second edition. Mori E, et al : Guidelines for management of idiopathic (2013) multiple hospitals. Int Psychogeriatr, 25, symptoms in patients with dementia : a cohort study in stay for the treatment of severe neuropsychiatric Sugiyama H, et al :Predictors of prolonged hospital (1999) CLINICIAN Ê16 NO

16 13 CLINICIAN Ê16 NO. 645

17 CLINICIAN Ê16 NO

18 CT DVD NST /ARB FAX 15 CLINICIAN Ê16 NO. 645

19 M M CT scan CT ECG CT CT ECG CLINICIAN Ê16 NO

20 17 CLINICIAN Ê16 NO. 645 Hand book,

21 CLINICIAN Ê16 NO inform inform

22 19 CLINICIAN Ê16 NO mg mg mg mg.. mmhg mmhg 180/110

23 CLINICIAN Ê16 NO Brose M, et al:sorafenib in radioactive iodinerefractory, locally advanced or metastatic differentiated thyroid cancer :a randomized, double-blind, phase 3 trial. Lancet, 384 (9940), (2014) Schlumberger M, et al :Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Eng J Med, 372 (7), (2015) Team Nexavar

24 21 CLINICIAN Ê16 NO. 645 Advance Care Planning

25 CLINICIAN Ê16 NO

26 23 CLINICIAN Ê16 NO. 645

27 CLINICIAN Ê16 NO

28 25 CLINICIAN Ê16 NO. 645

29 CLINICIAN Ê16 NO

30 27 CLINICIAN Ê16 NO. 645

31 CLINICIAN Ê16 NO high resolution manometry

32 29 CLINICIAN Ê16 NO. 645

33 CLINICIAN Ê16 NO Yoshikawa H, et al:oral symptoms including dental erosion in gastroesophageal reflux disease are associated with decreased salivary flow volume and swallowing function. J Gastroenterol, 47, (2012) Adachi K, et al :Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol, 16, (2001) Mizuta A, et al:different sex-related influences of eating habits on the prevalence of reflux esophagitis in Japanese. J Gastroenterol Hepatol, 26, (2011)

34 31 CLINICIAN Ê16 NO. 645 Nutritional Support Team Inflammatory bowel disease

35 CLINICIAN Ê16 NO

36 33 CLINICIAN Ê16 NO. 645

37 CLINICIAN Ê16 NO IBD IBD IBD IBD IBD 2030

38 35 CLINICIAN Ê16 NO. 645

39 CLINICIAN Ê16 NO Treat to Target csdmard

40 37 CLINICIAN Ê16 NO. 645 csdmard csdmard MSW RA

41 CLINICIAN Ê16 NO

42 39 CLINICIAN Ê16 NO. 645

43 CLINICIAN Ê16 NO benefit pt-global-vas unmet medical needs

44 41 CLINICIAN Ê16 NO. 645

45 CLINICIAN Ê16 NO

46 43 CLINICIAN Ê16 NO

47 CLINICIAN Ê16 NO

48 45 CLINICIAN Ê16 NO. 645 Interdisciplinary

49 CLINICIAN Ê16 NO Barsky AJ, Borus JF:Functional somatic syndromes. Ann Intern Med, 130 (11), (1999) Del Fabbro E : Assessment and management of chemical coping in patients with cancer. JCO, 32, (2014)

50 47 CLINICIAN Ê16 NO. 645

51 CLINICIAN Ê16 NO

52 49 CLINICIAN Ê16 NO. 645

53 CLINICIAN Ê16 NO

54 51 CLINICIAN Ê16 NO. 645

55 CLINICIAN Ê16 NO

56 53 CLINICIAN Ê16 NO. 645

57 CLINICIAN Ê16 NO

58 55 CLINICIAN Ê16 NO. 645

59 CLINICIAN Ê16 NO

60 57 CLINICIAN Ê16 NO. 645

61 CLINICIAN Ê16 NO rt-pa Drip, Ship and Retrieve

62 59 CLINICIAN Ê16 NO. 645 mrs:modified Rankin Scale, FIM:Functional Independence Measure, BI:Barthel Index, NIHSS: National Institute of Health Stroke Scale, JCS:Japan Coma Scale

63 CLINICIAN Ê16 NO

64 61 CLINICIAN Ê16 NO. 645 No.

65 CLINICIAN Ê16 NO

66 63 CLINICIAN Ê16 NO. 645 Hurthle mci....., p<. Hurthle mci....., p<.

67 CLINICIAN Ê16 NO

68 65 CLINICIAN Ê16 NO

69 CLINICIAN Ê16 NO Brose MS, et al:sorafenib in radioactive iodinerefractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial. Lancet, 384, (2014) Schlumberger M, et al:lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N Engl J Med, 372, (2015)

70 67 CLINICIAN Ê16 NO. 645

71 CLINICIAN Ê16 NO

72 69 CLINICIAN Ê16 NO. 645

73 ②超音波検査 US 数の年度別推移 㻝㻥㻥㻡 㻝㻝㻘㻤㻝㻞 㻝㻥㻥㻢 㻝㻟㻘㻢㻣㻡 㻝㻥㻥㻣 㻝㻠㻘㻤㻤㻝 㻝㻥㻥㻤 㻝㻢㻘㻞㻤㻡 㻝㻥㻥㻥 㻝㻣㻘㻡㻥㻢 㻞㻜㻜㻜 㻝㻤㻘㻝㻤㻢 㻞㻜㻜㻝 㻞㻜㻘㻜㻟㻞 㻞㻜㻜㻞 㻞㻜㻘㻢㻞㻢 㻞㻜㻜㻟 㻞㻞㻘㻡㻣㻡 㻞㻜㻜㻠 㻞㻟㻘㻣㻤㻠 㻞㻜㻜㻡 㻞㻠㻘㻥㻞㻝 㻞㻜㻜㻢 㻞㻠㻘㻝㻥㻜 㻞㻜㻜㻣 㻞㻡㻘㻝㻡㻠 㻞㻜㻜㻤 㻞㻠㻘㻢㻟㻡 㻞㻜㻜㻥 㻞㻠㻘㻥㻟㻣 㻞㻜㻝㻜 㻞㻠㻘㻝㻞㻣 㻞㻜㻝㻝 㻞㻠㻘㻥㻞㻣 㻞㻜㻝㻞 㻞㻠㻘㻜㻣㻝 㻞㻜㻝㻟 㻞㻠㻘㻝㻜㻠 㻞㻜㻝㻠 㻞㻞㻘㻞㻥㻣 年 2004年以降はプラトーである ③細胞診検査数の年度別推移 㻝㻥㻥㻡 㻥㻜㻜 㻝㻥㻥㻢 㻝㻘㻜㻞㻝 㻝㻥㻥㻣 㻝㻘㻝㻠㻢 㻝㻥㻥㻤 㻝㻘㻝㻞㻟 㻝㻥㻥㻥 㻝㻘㻞㻞㻠 㻞㻜㻜㻜 㻝㻘㻜㻢㻠 㻞㻜㻜㻝 㻝㻘㻝㻢㻝 㻞㻜㻜㻞 㻝㻘㻜㻡㻝 㻞㻜㻜㻟 㻝㻘㻝㻡㻝 㻞㻜㻜㻠 㻝㻘㻝㻟㻝 㻞㻜㻜㻡 㻝㻘㻞㻠㻞 㻞㻜㻜㻢 㻝㻘㻝㻞㻜 㻞㻜㻜㻣 㻝㻘㻜㻢㻢 㻞㻜㻜㻤 㻝㻘㻜㻣㻡 㻞㻜㻜㻥 㻝㻘㻜㻟㻜 㻞㻜㻝㻜 㻥㻟㻣 㻞㻜㻝㻝 㻝㻘㻜㻝㻜 㻞㻜㻝㻞 㻥㻟㻣 㻞㻜㻝㻟 㻤㻢㻟 㻞㻜㻝㻠 㻤㻝㻣 年 2005年をピークに減少傾向にある これは針生検 CNB やマンモトーム MMT 検査の 増加によるものである (72) CLINICIAN Ê16 NO

74 71 CLINICIAN Ê16 NO. 645 LH-

75 CLINICIAN Ê16 NO RH agonist tachyphylaxis

76 73 CLINICIAN Ê16 NO. 645

77 CLINICIAN Ê16 NO News letter News letter

78 75 CLINICIAN Ê16 NO. 645

79 CLINICIAN Ê16 NO

80 77 CLINICIAN Ê16 NO. 645

81 CLINICIAN Ê16 NO

82 79 CLINICIAN Ê16 NO. 645

83 CLINICIAN Ê16 NO

84 81 CLINICIAN Ê16 NO. 645

85 CLINICIAN Ê16 NO

86 83 CLINICIAN Ê16 NO

87 CLINICIAN Ê16 NO

88 85 CLINICIAN Ê16 NO % 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

89 CLINICIAN Ê16 NO

90 87 CLINICIAN Ê16 NO. 645

91 CLINICIAN Ê16 NO End of Life care

92 89 CLINICIAN Ê16 NO. 645

93 CLINICIAN Ê16 NO Step 1 Step 5 Step 5

94 91 CLINICIAN Ê16 NO. 645

95 CLINICIAN Ê16 NO

96 93 CLINICIAN Ê16 NO. 645

97 CLINICIAN Ê16 NO

98 95 CLINICIAN Ê16 NO. 645

99 CLINICIAN Ê16 NO NHS End of Life Care Programme publication supported by NCPC :Advance Care Planning :A Guide for Health and Social Care Staff (2007) AdvanceCarePlanning.pdf

100 IBD 3I survey IBD RA RA RA conventional synthetic DMARDscsDMARDs 2015 SpA PsA JIA 97 CLINICIAN Ê16 NO. 645

101 CLINICIAN Ê16 NO Halichondrin B

102 99 CLINICIAN Ê16 NO. 645 VEHERI

103 CLINICIAN Ê16 NO

104 101 CLINICIAN Ê16 NO. 645 in vitro

105 CLINICIAN Ê16 NO Cortes J, et al : Eribulin monotherapy versus treatment of physician s choice in patients with metastatic breast cancer (EMBRACE) : a phase 3 open-label randomised study. Lancet, 377 (9769), (2011) Ali AM, Ueno T, et al :Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. Eur J Cancer, 47 (15), (2011) Shaked Y, et al :Rapid chemotherapy-induced acute endothelial progenitor cell mobilization:implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell, 14 (3), (2008) Tozer GM, et al :Disrupting tumour blood vessels. Nat Rev Cancer, 5 (6), (2005) Funahashi Y, et al:eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci, 105 (10), (2014) Kajiyama H, et al:chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol, 31 (2), (2007) Li QQ, et al:twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res, 15 (8), (2009) Yoshida T, et al:eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition

106 signaling. J Biol Chem, 284 (34), (2009) activation of urokinase receptor-dependent cell transition (EMT) induced in breast cancer cells by Jo M, et al:reversibility of epithelial-mesenchymal 305 (2008) 1alpha promotes metastasis. Nat Cell Biol, 10 (3), 295- Yang MH, et al :Direct regulation of TWIST by HIF- (MET) states. Br J Cancer, 110 (6), (2014) 103 CLINICIAN Ê16 NO. 645

107 CLINICIAN Ê16 NO response rate progression-free survival overall survival quality of life

108 105 CLINICIAN Ê16 NO. 645 luminal vascular endothelial growth factor P< log-rank P= positive study

109 CLINICIAN Ê16 NO survival post-progression post-progression survival P=0.03 log-rank

110 107 CLINICIAN Ê16 NO. 645 P=0.01 log-rank response evaluation criteria in solid tumours

111 CLINICIAN Ê16 NO Seah DS, et al :Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw, 12 (1), (2014) Miller K, et al:paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357, (2007) Broglio KR, Berry DA:Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst, 101 (23), (2009) Cortes J, et al : Eribulin monotherapy versus treatment of physician s choice in patients with metastatic breast cancer (EMBRACE):a phase 3 open-label randomised study. Lancet, 377, (2011) Twelves C, et al :Efficacy of eribulin in women with metastatic breast cancer:a pooled analysis of two phase 3 studies. Breast Cancer Res Treat, 148 (3), (2014) Watanabe J:Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world:a single institutional review. SpringerPlus, 4, 625 (2015)

112 CLINICIAN Ê16 NO

113

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案) VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.

More information

表1.eps

表1.eps Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol

More information

食道がん化学放射線療法後のsalvage手術

食道がん化学放射線療法後のsalvage手術 2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573

More information

スライド 1

スライド 1 QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014

More information

32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ

32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ 29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27

More information

1_2.eps

1_2.eps 第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075

More information

PowerPoint プレゼンテーション

PowerPoint プレゼンテーション * ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1

More information

Gynecologic Oncology Trial and Investigation Consortium GOTIC-002

Gynecologic Oncology Trial and Investigation Consortium GOTIC-002 Gynecologic Oncology Trial and Investigation Consortium GOTIC-002 3 8 ...2...2...2...2...3...4...4...5...9...9...9...9...9... 13... 13... 13... 13... 13... 13... 13... 14... 14... 15... 15... 15...

More information

東洋医学雑誌

東洋医学雑誌 Vol.67 No.2 123-130, 2016 Akiyo GUSHI a Chihaya KORIYAMA b Ryo YOSHINAGA c Hiromi YANO c Junichi TSUMAGARI d Eiichi TAHARA c a Gushi Dermatological Clinic, 45-3 Higashiohsyoji, Satsumasendai city, Kagoshima

More information

26 1 : Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hira

26 1 : Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hira 26 1 : 35 45 2017 1 2 2 2 2 2 2 2 2 1 1 2 Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hirayama 1, Yoko Nakajo 2, Akemi Saito 2, Rie Hatakeyama

More information

Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 8 (2010) Key words Neuropsychopharmacology Neuroscientist Curr Opin Neurol Clin Rehabil J Neurol Neurosurg Psychiatry

More information

Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,

More information

_’£”R‡Ù‡©

_’£”R‡Ù‡© 29 31 38 2008 31 1) 2) 2) 3) 2) 1) 2008 302008 12 Activities of Daily Living ADL ADL 42 ADL ADL 1990 QOL Quality of Life QOL 1 QOL // 2 Activity of Daily Living ADL Performance Status PS ADL 3 1) 2) 3)

More information

C/NC : committed/noncommitted

C/NC : committed/noncommitted C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a

More information

; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9

; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9 32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5

More information

本文.indd

本文.indd CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study

More information

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate 37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5

More information

untitled

untitled 19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- [email protected] http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase

More information

終末期癌患者に対する 輸液治療の是非

終末期癌患者に対する 輸液治療の是非 3 A B NSAID D Case stories A B NSAID D Case stories A. IASP Task Force on Taxonomy WHO Collaborating Center for Palliative Cancer Care : Looking forward to cancer pain relief for all. CBC Oxford, Oxford,

More information

2001 2003 2005 2006 2007 2008

2001 2003 2005 2006 2007 2008 2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65

More information

VOL.42 S-1

VOL.42 S-1 CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical

More information

20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of

More information

untitled

untitled 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J

More information

Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;

More information

_02.indd

_02.indd 30, 11-16, 2010 Z Z score Computed tomography ROC analysis 3 CT 1,2 CT 1/3 3 5 CT CT 6 7,8 MCA ASPECTS Alberta Stroke Programme Early CT Score 4 10 CT ASPECTS 50% 9 Z 10 CT Z CT 10 Z Z Z receiver operating

More information

1) Delbet P: Retrocissement du choledoque. Cholecysto-duodenostomie. Bull Mem Soc Nat Chir 50: 1144-1146, 1924 2) Wiesner RH, LaRusso NF: Clinicopathologic Features of the Syndrome of Primary Sclerosing

More information

VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3

VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%

More information

36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi

36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi 36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: 378 384, 2014 1 2 要旨 1999 2012 10 31 29 26 80 30 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visit time, chronological change はじめに 4 12 23 27 1 Japan

More information

CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection

More information

Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents

Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)

More information

A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc

A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, School of Medicine, Tokushima University, Tokushima Fetal

More information

1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):

More information

PubMed 1. CD-ROM MEDLINE MeSH PubMed 2. Automatic Term Mapping MeSH 3. Related Article 1 1. 2. MeSH Browser MeSH PreMEDLINE MeSH -2-

PubMed 1. CD-ROM MEDLINE MeSH PubMed 2. Automatic Term Mapping MeSH 3. Related Article 1 1. 2. MeSH Browser MeSH PreMEDLINE MeSH -2- PubMed MEDLINE NLM 1879 Index Medicus 1960 MEDLARS Medical Literature Analysis and Retrieval System 1970 MEDLINE MEDlars online 1966 70 4,000 170 PubMed MEDLINE NLM National Center for Biotechnology Information

More information

終末期の呼吸困難症状への対応*松坂最終修正

終末期の呼吸困難症状への対応*松坂最終修正 Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,

More information

<95DB8C9288E397C389C88A E696E6462>

<95DB8C9288E397C389C88A E696E6462> 2011 Vol.60 No.4 p.332 338 Usefulness of regional education program for dietary salt reduction: Self-monitoring of urinary salt excretion Kenichiro YASUTAKE[1] Kayoko SAWANO[1] Shoko YAMAGUCHI[1] Hiroko

More information

NL10

NL10 Information September, 2006 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.10 September, 2006 3 2006 4 Japanese Association for Molecular Target Therapy of Cancer News Letter

More information

268 LSG 図 Lee ABCD 表 1 4 Age BMI C Duration Still DiaRem 表 1 4 HbA1c Ⅱ 対象と方法 1 17 LSG 6 3 Excess Weight Loss EWL BMI 25 kg/m 2 Hb

268 LSG 図 Lee ABCD 表 1 4 Age BMI C Duration Still DiaRem 表 1 4 HbA1c Ⅱ 対象と方法 1 17 LSG 6 3 Excess Weight Loss EWL BMI 25 kg/m 2 Hb 52 5 18 1 267 原著 ( 臨床研究 ) LSG ABCD DiaRem LSG 3 93.1 1 7.8 CR37.5 PR33.3 1 ABCD 5 DiaRem 12 LSG ABCD DiaRem LSG 腹腔鏡下スリーブ状胃切除術,ABCD スコア,DiaRem スコア Ⅰ はじめに Bariatric Surgery 2 1 metabolic surgery 2 ABCD 2

More information

2

2 2010 ANNUAL REPORT AIZAWA HOSPITAL 2 ANNUAL REPORT AIZAWA HOSPITAL 2 巻頭言 本年の大きな出来事はなんと言っても 3 月 11 日に起こったマグニチュード9 の東日本大震災であろう 被災された皆様には心からお見舞いを申し上げる この震災は想定外であるとされた 想定外 とは何か? 議論が沸騰したが結論も出ず うやむやのうちに収束してしまった感を持つのは私だけであろうか?

More information

4703ALL01

4703ALL01 473201010 *** (1999) 16 2017 20023 2 1 2 1220 (1999a),(1999b) (1998), (2002) (2003)(1999)(2003) Conjoint Analysis Conjoint Analysis Willingness to PayStandard gamble Time trade-off Rating Scale Willingness

More information

図 1 緩和ケアチーム情報共有データベースの患者情報画面 1 患者氏名, 生年月日, 性別, 緩和ケアチームへの依頼内容について,2 入退院記録, 3カンファレンス ラウンド実施一覧,4 問題点のリスト,5 介入内容の記録. 図 2 緩和ケアチームカンファレンス ラウンドによる患者評価入力画面 (

図 1 緩和ケアチーム情報共有データベースの患者情報画面 1 患者氏名, 生年月日, 性別, 緩和ケアチームへの依頼内容について,2 入退院記録, 3カンファレンス ラウンド実施一覧,4 問題点のリスト,5 介入内容の記録. 図 2 緩和ケアチームカンファレンス ラウンドによる患者評価入力画面 ( 2015; 10(2): 901 5 活動報告 緩和ケアチームデータベースの改良に向けた取り組み 渡邊裕之 1,4), 江藤美和子 2,4) 3,4), 山﨑圭一 1 2 3 4 受付日 2014 年 9 月 10 日 / 改訂日 2015 年 1 月 29 日 / 受理日 2015 年 2 月 3 日 2011 年に, ベルランド総合病院緩和ケアチーム ( 以下,PCT) で構築した PCT 情報共有データベース

More information

et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology

et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology 37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the

More information

1. Sugimura, T. and Fujimura, S.: Tumor production in glandular stomach of rat by N-methyl-N'-nitro- N-nitrosoguanidine. Nature, 216, 943-944, 1967. 2. Fujimura, S., Kogure, K., Sugimura, T. and Takayama,

More information

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels

More information

E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian

More information

Fig. 1 Chemical structure of DL-8280

Fig. 1 Chemical structure of DL-8280 Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.

More information

The Japanese Journal of Health Psychology, 29(S): (2017)

The Japanese Journal of Health Psychology, 29(S): (2017) Journal of Health Psychology Research 2017, Vol. 29, Special issue, 139 149Journal of Health Psychology Research 2016, J-STAGE Vol. Advance 29, Special publication issue, 139 149 date : 5 December, 2016

More information

日本消化器外科学会雑誌第30巻第3号

日本消化器外科学会雑誌第30巻第3号 Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment

More information

Endocrinological and statistical analysis of ovarian function in hysterectomized patients Masaya HAYAFUJI, Kazuaki KATAYAMA and Matsuto MOCHIZUKI Depa

Endocrinological and statistical analysis of ovarian function in hysterectomized patients Masaya HAYAFUJI, Kazuaki KATAYAMA and Matsuto MOCHIZUKI Depa Endocrinological and statistical analysis of ovarian function in hysterectomized patients Masaya HAYAFUJI, Kazuaki KATAYAMA and Matsuto MOCHIZUKI Department of Obstetrics and Gynecology, Kobe University

More information

indd

indd Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf

More information

審査報告書(案)

審査報告書(案) 19 83 7 18 628 1 19 8 3 7 18 6 28 30 MI 31 360 21700BZY00247000 5mm CEA 59 mm 2 50% 80 1. 2. 3 19 8 3 [ ] 7 [ ] [ ] [ ] [ ] 18 6 28 [ ] CEA 49mm 50 80 2 4 carotid endarterectomy CEA 1,2 CEA ECST 3 NASCET

More information

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio 7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine

More information

437“ƒ

437“ƒ et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer

More information

Unknown

Unknown Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.2, No.3 July 2013 Report The 30 th Meeting of Japan Association of Breast and Thyroid Sonology... 1 Department of Organ

More information

胆石症

胆石症 ,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic

More information

Fig. 1 Chemical structure of KW-1070

Fig. 1 Chemical structure of KW-1070 Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.

More information

_念3)医療2009_夏.indd

_念3)医療2009_夏.indd Evaluation of the Social Benefits of the Regional Medical System Based on Land Price Information -A Hedonic Valuation of the Sense of Relief Provided by Health Care Facilities- Takuma Sugahara Ph.D. Abstract

More information

Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004

Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004 The Journal of the Japan Academy of Nursing Administration and Policies Vol 8, No 1, pp 43 _ 57, 2004 The Literature Review of the Japanese Nurses Job Satisfaction Research Which the Stamps-Ozaki Scale

More information

Diagnosis of Dementia: Update

Diagnosis of Dementia: Update 10 C A 1 2 Normal SMI MCI Early Dementia B Moderate Dementia 3 Severe Dementia 4 5 D AD, VD, FTD, DLB, PDD Depression Dementia d/t GMC Modifiable risk factors and preventive factors for dementia 6-5 -

More information

日本皮膚科学会第121巻第9号

日本皮膚科学会第121巻第9号 Appl Nurs Res Wound Repair Regen Int Wound J Adv Skin Wound Care Ostomy Wound Manage Wound Repair Regen Int J Nurs Stud JAdvNurs Visual Dermatology J Adv Nurs Appl Nurs Res Cochrane Database Syst Rev

More information